<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732951</url>
  </required_header>
  <id_info>
    <org_study_id>1320.22</org_study_id>
    <secondary_id>2015-003529-33</secondary_id>
    <nct_id>NCT02732951</nct_id>
  </id_info>
  <brief_title>Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema</brief_title>
  <official_title>A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Pharmacodynamics, Safety and Tolerability of Orally Administered BI 1026706 for 12 Weeks in Patients With Mild Visual Impairment Due to Center-involved Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal
      thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12
      weeks in patients with mild vision impairment due to center-involved DME
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">October 23, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Central subfield thickness (CSFT) in the study eye at week 12 as assessed by Spectral-Domain Optical Coherence Tomography</measure>
    <time_frame>baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency (in percent) of adverse events over the treatment period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>BI 1026706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <arm_group_label>BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients 18 years of age and older

          -  Male patients or female patients of non-childbearing potential

          -  Diagnosis of Diabetes mellitus type 1 or type 2

          -  Retinal thickening due to Diabetic macular edema (DME) involving the center of the
             macula in the study eye as confirmed by the Investigator on clinical exam

          -  Center-involved DME confirmed on Spectral-Domain Optical Coherence Tomography (SD-OCT)
             with central subfield thickness (CSFT) of at least 300 µm in the study eye at
             screening, confirmed by Central Reading Centre

          -  Best corrected visual acuity ETDRS (Early Treatment Diabetic Retinopathy Study) letter
             score in the study eye of 84 or below, but at least 70 at screening

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Macular edema considered to be due to other causes than DME in the study eye

          -  Additional eye disease in the study eye that, in the opinion of the Investigator,
             might affect macular edema or could compromise or alter visual acuity during the
             course of the trial

          -  Anterior segment and vitreous abnormalities in the study eye that would compromise the
             adequate assessment of the best corrected visual acuity or an adequate examination of
             the posterior pole

          -  Intraocular surgery in the study eye within 4 months prior to randomization or planned
             intraocular surgery, including cataract, during the study period

          -  Proliferative diabetic retinopathy or iris neovascularisation in the study eye

          -  Aphakia in the study eye

          -  Any indication that requires immediate treatment or for which treatment is expected in
             the study eye with anti-Vascular Endothelial Growth Factor (VEGF) or with laser
             photocoagulation during the period, as per Investigator's judgment

          -  History of prior laser photocoagulation or other surgical, intravitreal or peribulbar
             treatment in the study eye within 4 months prior to randomization, either for DME or
             an ocular condition other than DME

          -  History of fluocinolone acetonide intravitreal implant in the study eye

          -  Application of intraocular corticosteroids in the study eye within 2 years prior to
             randomization in phakic eyes or 9 months in pseudophakic eyes

          -  History of topical steroid or nonsteroidal anti-inflammatory drugs (NSAID) treatment
             in the study eye within 30 days prior to randomization

          -  Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization

          -  Initiation of intensive insulin treatment (multiple daily injections or a pump) within
             3 months prior to randomization or plans to do so in the next 4 months

          -  Change in oral antidiabetic medication within 3 months prior to randomization

          -  Patients with a clinically relevant abnormal screening haematology, blood chemistry,
             or urinalysis

          -  Renal impairment with estimated creatinine clearance &lt; 30 mL/min (as calculated by
             Cockcroft-Gault equation)

          -  Myocardial infarction or unstable angina pectoris within 3 months before randomization

          -  Uncontrolled arterial hypertension defined as a single measurement of systolic &gt;180
             mmHg, two consecutive measurements of systolic &gt;160 mmHg, or diastolic &gt;100mmHg on
             optimal medical regimen

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brussels-UNIV Brugmann -Horta</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leuven - UNIV UZ Leuven (Sint-Rafaël)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp National 15-20, Ophtalmo, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Pierre Paul Riquet</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augen Zentrum Nordwest, Ahaus</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamppeter Augenzentrum, Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95444</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenarzt Dr. Dunker und Kollegen, Troisdorf</name>
      <address>
        <city>Troisdorf-Sieglar</city>
        <zip>53844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon, Panepistimiako Geniko Nosokomeio</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Herakleion,Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Street Hospital, Ophtalmology Department, Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAZ County Hospital, Ophtalmology Department, Miskolc</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.Szeged;Szent-Gyorgyi;Albert Heal.Cent.Ophtalmology Dep</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga-Escala Braga</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIBILI - Association for Innovation and Biomedical Research on Light and Image</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar São João,EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Vila Franca de Xira</name>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmología Barraquer</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dos de Maig</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Gómez-Ulla</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

